The Valley Desk

Clinical trial reportThe pharmacogenomics journalPublished

Contribution of plasma levels of VEGF-A and angiopoietin-2 in addition to a genetic variant in KCNAB1 to predict the risk of bevacizumab-induced hypertension

Read the publication ↗ Open access copy ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Thomas Jefferson University Hospital, with Jefferson Health linked by the institution reference. Affiliation source

Publication record

Type
Clinical trial report
Venue
The pharmacogenomics journal
Published
Subject terms
Humans; Neoplasms; Hypertension; Angiogenesis Inhibitors; Angiopoietin-2; Vascular Endothelial Growth Factor A; Risk Factors; Polymorphism, Single Nucleotide; Adult; Aged; Middle Aged; Female
PubMed ID
38992025
PubMed Central ID
PMC11374128
Added to directory
Source checked

Report a correction or request removal